Your Meds Aren't Working at Standard Doses. Your Genes May Explain Why.

CYP2D6 is one of the most important drug-metabolizing enzymes in your liver. It handles roughly one out of every four medications you take, from SSRIs to opioids to beta-blockers to codeine. This enzyme is the gatekeeper for a huge range of psychiatric, cardiovascular, and pain medications.

Here’s the problem: CYP2D6 comes in many genetic flavors. Some people carry variants like *4, *10, or *17 that reduce enzyme activity. Poor metabolizers, carrying roughly 7 to 10% of people with European ancestry, have significantly reduced or absent enzyme function. With CYP2D6, you can also inherit extra gene copies, making you an ultra-rapid metabolizer.

Poor metabolizers accumulate toxic levels of drugs; ultra-rapid metabolizers get no therapeutic effect at all. If you’re a poor metabolizer of antidepressants, a standard dose can cause overwhelming side effects. If you’re ultra-rapid, you need 2 to 3 times the standard dose just to feel anything. Many people spend years on the wrong medication or the wrong dose without ever knowing their CYP2D6 status.

CYP2C19 metabolizes a different set of drugs: many antidepressants, proton pump inhibitors used for acid reflux, and clopidogrel, a blood thinner used after heart stents. This enzyme is particularly critical for clopidogrel, which is actually a prodrug, meaning your body has to activate it to make it work.

Variants like *2 and *3 make you a poor metabolizer, seen in roughly 2 to 15% of the population depending on ancestry. Rapid metabolizer variants like *17 exist as well. The clinical consequence is severe and sometimes life-threatening. Poor metabolizers of clopidogrel don’t activate the drug and get zero antiplatelet protection after a stent, which means clot risk. Conversely, ultra-rapid metabolizers of SSRIs need much higher doses to feel an effect.

If you’re a poor metabolizer of clopidogrel, a standard dose offers no cardiac protection whatsoever. If you’re a poor metabolizer of an SSRI like escitalopram, you may need to go much higher than normal dosing to achieve benefit. This is one of the few genes where testing is actually starting to become standard in cardiology, because the stakes are literally life and death.

CYP2C9 metabolizes warfarin, a blood thinner that millions of people take. It also handles NSAIDs like ibuprofen and naproxen, as well as some statins. Warfarin has a narrow therapeutic window, meaning the difference between an effective dose and a bleeding dose is small.

Variants *2 and *3 reduce enzyme activity. Roughly 5 to 10% of people with European ancestry carry these variants. Poor metabolizers clear warfarin much more slowly than expected. Standard dosing in a poor metabolizer leads to dangerously high blood levels and bleeding risk.

Poor metabolizers of warfarin can suffer major bleeding events on standard doses. This is why warfarin dosing now includes CYP2C9 testing at most hospitals. If you’re a poor metabolizer, your therapeutic dose is often 30 to 50% lower than the standard population dose. If you carry a rapid metabolizer variant, you may need higher doses to achieve anticoagulation.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that warfarin directly inhibits. This gene isn’t about metabolism; it’s about the target of warfarin itself. The variant -1639G>A affects the amount of VKORC1 enzyme you produce.

The A allele appears in roughly 40% of people with European ancestry and in even higher frequencies in Asian and African populations. People with the A allele produce less VKORC1 enzyme, meaning warfarin has a more powerful effect on less drug.

If you carry the A allele, you are exquisitely sensitive to warfarin and require significantly lower doses. Standard warfarin dosing in someone with the A allele can cause excessive anticoagulation and bleeding. The G allele carriers, by contrast, need more warfarin to achieve the same effect. VKORC1 testing is now standard practice in anticoagulation clinics because the difference is so clinically important.

SLCO1B1 encodes a transporter protein that pulls statins into liver cells, where they do their job of lowering cholesterol. This transporter is critical for statin efficacy and safety. The variant rs4149056 (the *5 allele) reduces transporter function.

The C allele, which impairs transporter function, appears in roughly 15% of the population. When you carry this variant, statins don’t get pulled into liver cells efficiently. Instead, they stay in the bloodstream longer, at higher concentrations.

Carriers of the SLCO1B1 *5 variant have elevated systemic statin exposure, especially with simvastatin, leading to increased myopathy and muscle pain risk. You’re not weak or lazy; your cells are being exposed to higher statin levels than your genes can safely handle. This variant is particularly critical for simvastatin, less so for pravastatin or rosuvastatin, which don’t depend as heavily on this transporter.

MTHFR encodes methylenetetrahydrofolate reductase, an enzyme central to the methylation cycle. This cycle is foundational to DNA synthesis, neurotransmitter production, and drug metabolism. The C677T variant reduces enzyme efficiency.

Approximately 40% of people with European ancestry carry at least one copy of the 677T variant. Homozygotes carry two copies and have substantially reduced MTHFR enzyme activity. This affects your ability to metabolize drugs that depend on folate-mediated pathways, including methotrexate, certain chemotherapy agents, and some psychiatric medications.

MTHFR variants impair the folate-dependent metabolic pathways that activate or clear some drugs, altering their efficacy and safety. If you’re homozygous for MTHFR C677T and taking methotrexate, your doctor needs to know this to adjust dosing. Similarly, if you take certain antidepressants or folate-dependent chemotherapy, MTHFR status changes how your body handles these drugs.